The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Desoxyn     (2S)-N-methyl-1-phenyl- propan-2-amine

Synonyms: Desyphed, Stimulex, Norodin, Crank, Speed, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Metamfetamine

 

Psychiatry related information on Metamfetamine

 

High impact information on Metamfetamine

  • CONCLUSIONS: This evidence suggests that the duplication might have a role in regulating the expression of the DRD4 gene and provides an understanding of the biological mechanisms underlying the etiology of neuropsychiatric disorders such as ADHD, schizophrenia, and metamphetamine abuse [12].
  • However, the area under the serum concentration-time curve (AUC) values of l-methamphetamine were, on average, 46% higher (P = .01) in poor metabolizers than in extensive metabolizers [13].
  • In contrast, l-methamphetamine, the major metabolite of l-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior [14].
  • To address this possibility, we examined the effects of MPTP or METH in mice lacking genes encoding IL-6, CCL2 or TNF receptor (TNFR)1/2 [15].
  • RESULTS: Detection limits in whole blood for morphine, D-methamphetamine, nordiazepam, benzoylecgonine, nordiazepam, PCP, and L-11-nor-9-carboxy-delta9-THC were 3, 2, <4, 5, 25, and 3 microg/L, respectively, for the STC ELISAs [16].
 

Chemical compound and disease context of Metamfetamine

 

Biological context of Metamfetamine

 

Anatomical context of Metamfetamine

 

Associations of Metamfetamine with other chemical compounds

 

Gene context of Metamfetamine

 

Analytical, diagnostic and therapeutic context of Metamfetamine

References

  1. Extrapyramidal motor symptoms versus striatal infarction volume after focal ischemia in mongolian gerbils. Ishibashi, S., Kuroiwa, T., Katsumata, N., Yuan, S.L., Endo, S., Mizusawa, H. Neuroscience (2004) [Pubmed]
  2. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Bowyer, J.F., Ali, S. Synapse (2006) [Pubmed]
  3. Determination of l-methamphetamine: a case history. Wyman, J.F., Cody, J.T. Journal of analytical toxicology. (2005) [Pubmed]
  4. Effects of methamphetamine and methyldopa on ethanol induced hypothermia in mice. Ageel, A.M., Ginawi, O.T. Jpn. J. Pharmacol. (1985) [Pubmed]
  5. High HIV-1 prevalence among metamphetamine users in central Thailand, 1999-2000. Vongsheree, S., Sri-Ngam, P., Ruchusatsawat, N., Thaisri, H., Puangtabtim, W., Phutiprawan, T., Sawanpanyalert, P. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. (2001) [Pubmed]
  6. Methamphetamine enhances histoplasmosis by immunosuppression of the host. Martinez, L.R., Mihu, M.R., Gácser, A., Santambrogio, L., Nosanchuk, J.D. J. Infect. Dis. (2009) [Pubmed]
  7. The bioavailability of intranasal and smoked methamphetamine. Harris, D.S., Boxenbaum, H., Everhart, E.T., Sequeira, G., Mendelson, J.E., Jones, R.T. Clin. Pharmacol. Ther. (2003) [Pubmed]
  8. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Engberg, G., Elebring, T., Nissbrandt, H. J. Pharmacol. Exp. Ther. (1991) [Pubmed]
  9. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: a study of D- and L-derivatives in canine narcolepsy. Kanbayashi, T., Honda, K., Kodama, T., Mignot, E., Nishino, S. Neuroscience (2000) [Pubmed]
  10. Effects of d-methamphetamine on auditory and visual reaction times and detection thresholds in the baboon. Hienz, R.D., Lukas, S.E., Brady, J.V. Psychopharmacology (Berl.) (1985) [Pubmed]
  11. Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains. Kitahama, K., Valatx, J.L. Psychopharmacology (Berl.) (1979) [Pubmed]
  12. Functional effects of a tandem duplication polymorphism in the 5'flanking region of the DRD4 gene. D'Souza, U.M., Russ, C., Tahir, E., Mill, J., McGuffin, P., Asherson, P.J., Craig, I.W. Biol. Psychiatry (2004) [Pubmed]
  13. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin, H., Anttila, M., Dahl, M.L., Karnani, H., Nyman, L., Taavitsainen, P., Pelkonen, O., Bertilsson, L. Clin. Pharmacol. Ther. (1998) [Pubmed]
  14. Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Winger, G.D., Yasar, S., Negus, S.S., Goldberg, S.R. Clin. Pharmacol. Ther. (1994) [Pubmed]
  15. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. Sriram, K., Miller, D.B., O'Callaghan, J.P. J. Neurochem. (2006) [Pubmed]
  16. Comparison of ELISAs for opiates, methamphetamine, cocaine metabolite, benzodiazepines, phencyclidine, and cannabinoids in whole blood and urine. Kerrigan, S., Phillips Jr, W.H. Clin. Chem. (2001) [Pubmed]
  17. Psychophysical profiles differentiate drugs of abuse. Hienz, R.D., Brady, J.V. NIDA Res. Monogr. (1981) [Pubmed]
  18. Effects of isradipine, a dihydropyridine-class calcium channel antagonist, on D-methamphetamine-induced cognitive and physiological changes in humans. Johnson, B.A., Ait-Daoud, N., Wells, L.T. Neuropsychopharmacology (2000) [Pubmed]
  19. Specificity of an antibody directed against d-methamphetamine. Studies with rigid and nonrigid analogs. Faraj, B.A., Israili, Z.H., Kight, N.E., Smissman, E.E., Pazdernik, T.J. J. Med. Chem. (1976) [Pubmed]
  20. Effects of metamfetamine on auditory P3 component of event-related potentials in rats. Iwanami, A., Shinba, T., Sumi, M., Ozawa, N., Yamamoto, K. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1995) [Pubmed]
  21. Stage-specific effects of prenatal d-methamphetamine exposure on behavioral and eye development in rats. Acuff-Smith, K.D., Schilling, M.A., Fisher, J.E., Vorhees, C.V. Neurotoxicology and teratology. (1996) [Pubmed]
  22. Potentiation of lethality and increase in body temperature by combined use of d-methamphetamine and morphine in mice. Funahashi, M., Kohda, H., Shikata, I., Kimura, H. Forensic Sci. Int. (1988) [Pubmed]
  23. Fluoro-gold and pentamidine inhibit the in vitro and in vivo release of dopamine in the striatum of rat. Bowyer, J.F., Gough, B., Broening, H.W., Newport, G.D., Schmued, L. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  24. Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine. Ricaurte, G.A., Seiden, L.S., Schuster, C.R. Neuropharmacology (1983) [Pubmed]
  25. Effects of d-methamphetamine on monkey brain monoamine oxidase, in vivo and in vitro. Egashira, T., Yamamoto, T., Yamanaka, Y. Jpn. J. Pharmacol. (1987) [Pubmed]
  26. Presence of beta-arrestin in cellular inclusions in metamphetamine-treated PC12 cells. De Blasi, A., Capobianco, L., Iacovelli, L., Lenzi, P., Ferrucci, M., Lazzeri, G., Fornai, F., Picascia, A. Neurol. Sci. (2003) [Pubmed]
  27. The adverse effects of l-methamphetamine on the development of explanted rat embryos. Ozaki, T., Nakamura, Y., Saito, Y. Asia-Oceania journal of obstetrics and gynaecology / AOFOG. (1992) [Pubmed]
  28. Lobeline does not serve as a reinforcer in rats. Harrod, S.B., Dwoskin, L.P., Green, T.A., Gehrke, B.J., Bardo, M.T. Psychopharmacology (Berl.) (2003) [Pubmed]
  29. Effect of sub-chronic hydrocortisone on responses to amphetamine in normal male volunteers. Hearn, A.J., Gallagher, P., Owen, B.M., Smith, M.S., Watson, S., Young, A.H. Psychopharmacology (Berl.) (2004) [Pubmed]
  30. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H.J., Kovar, K.A., Lindenblatt, H., Hermle, L., Spitzer, M., Sass, H. Psychopharmacology (Berl.) (1999) [Pubmed]
  31. CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle. Vorhees, C.V., Reed, T.M., Schilling, M.A., Fisher, J.E., Moran, M.S., Cappon, G.D., Nebert, D.W. Neurotoxicology and teratology. (1998) [Pubmed]
  32. Effect of methamphetamine neurotoxicity on learning-induced Arc mRNA expression in identified striatal efferent neurons. Daberkow, D.P., Riedy, M.D., Kesner, R.P., Keefe, K.A. Neurotox. Res (2008) [Pubmed]
  33. The association study of DRD2, ACE and AGT gene polymorphisms and metamphetamine dependence. Serý, O., Vojtová, V., Zvolský, P. Physiological research / Academia Scientiarum Bohemoslovaca. (2001) [Pubmed]
  34. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Vorhees, C.V., Morford, L.L., Inman, S.L., Reed, T.M., Schilling, M.A., Cappon, G.D., Moran, M.S., Nebert, D.W. Pharmacogenetics (1999) [Pubmed]
  35. Protein tyrosine phosphatase alpha (PTP alpha) knockout mice show deficits in Morris water maze learning, decreased locomotor activity, and decreases in anxiety. Skelton, M.R., Ponniah, S., Wang, D.Z., Doetschman, T., Vorhees, C.V., Pallen, C.J. Brain Res. (2003) [Pubmed]
  36. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Haque, N.S., Hlavin, M.L., Fawcett, J.W., Dunnett, S.B. Brain Res. (1996) [Pubmed]
  37. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Laine, K., Anttila, M., Nyman, L., Wahlberg, A., Bertilsson, L. Eur. J. Clin. Pharmacol. (2001) [Pubmed]
  38. Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Matsuzawa, D., Hashimoto, K., Miyatake, R., Shirayama, Y., Shimizu, E., Maeda, K., Suzuki, Y., Mashimo, Y., Sekine, Y., Inada, T., Ozaki, N., Iwata, N., Harano, M., Komiyama, T., Yamada, M., Sora, I., Ujike, H., Hata, A., Sawa, A., Iyo, M. Am. J. Psychiatry (2007) [Pubmed]
  39. Lobeline attenuates d-methamphetamine self-administration in rats. Harrod, S.B., Dwoskin, L.P., Crooks, P.A., Klebaur, J.E., Bardo, M.T. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  40. Quantitative and isomeric determination of amphetamine and methamphetamine from urine using a nonprotic elution solvent and R(-)-alpha-methoxy-alpha-trifluoromethylphenylacetic acid chloride derivatization. Holler, J.M., Vorce, S.P., Bosy, T.Z., Jacobs, A. Journal of analytical toxicology. (2005) [Pubmed]
  41. Validation of the immunalysis microplate ELISA for the detection of methamphetamine in hair. Han, E., Miller, E., Lee, J., Park, Y., Lim, M., Chung, H., Wylie, F.M., Oliver, J.S. Journal of analytical toxicology. (2006) [Pubmed]
  42. GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. Valentine, J.L., Kearns, G.L., Sparks, C., Letzig, L.G., Valentine, C.R., Shappell, S.A., Neri, D.F., DeJohn, C.A. Journal of analytical toxicology. (1995) [Pubmed]
 
WikiGenes - Universities